The debut of autoimmune hepatitis after a new coronavirus infection (COVID-19) in an 11-month-old child
https://doi.org/10.31146/1682-8658-ecg-216-8-191-196
Abstract
In many countries fix cases of severe liver damage in children are recorded. A previous or existing coronavirus infection leads to a disruption in the body’s immune response to infections, which can lead to severe inflammation that caused liver damage. This article describes a clinical case of type 2 autoimmune hepatitis, a high degree of biochemical activity, that debuted in an 11-month-old child after a new coronavirus infection (COVID-19). The presented clinical example demonstrates the need for a thorough and comprehensive examination of children with the first clinical manifestations of liver damage and timely prescription of therapy
About the Authors
T. N. Lebedeva
Institution “Medical Academy named after S. I. Georgievsky” of Vernadsky CFU; “Republican сhildren’s clinical hospital” of the Ministry of Health of the Republic of Crimea
Russian Federation
Russian Federation
A. U. Marchukova
Institution “Medical Academy named after S. I. Georgievsky” of Vernadsky CFU; “Republican сhildren’s clinical hospital” of the Ministry of Health of the Republic of Crimea
Russian Federation
Russian Federation
K. G. Bondar
“Republican сhildren’s clinical hospital” of the Ministry of Health of the Republic of Crimea
Russian Federation
Russian Federation
References
1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006; 354:54-66. doi: 10.1056/NEJMra050408.
2. Union of Pediatricians of Russia. Clinical guidelines. Autoimmune hepatitis in children. 2016: 6 P. (in Russ.)@@ Союз педиатров России. Клинические рекомендации. Аутоиммунный гепатит у детей. 2016: 6 с
3. Gronbæk L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612-617. doi: 10.1016/j.jhep.2013.10.020.
4. Lohse A. W., Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011;55:171-182. doi: 10.1016/j.jhep.2010.12.012.
5. Zachou K., Muratori P., Koukoulis G. K., Granito A., Gatselis N., Fabbri A. et al. Review article: autoimmune hepatitis - Current management and challenges. Aliment Pharmacol Ther. 2013;38:887-913. doi: 10.1111/apt.12470.
6. Alvarez F., Berg P. A., Bianchi F. B. et al.International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. doi: 10.1016/s0168-8278(99)80297-9.
7. Hennes E. M., Zeniya M., Czaja A. J. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176. doi: 10.1002/hep.22322.
8. Manns M. P., Czaja A. J., Gorham J. D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213. doi: 10.1002/hep.23584.
9. Gleeson D., Heneghan M. A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-1629. doi: 10.1136/gut.2010.235259.
10. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Buschenfelde K. H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292-294. doi: 10.1016/s0140-6736(87)92024-1.
11. Boberg K. M., Chapman R. W., Hirschfield G. M. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374-385. doi: 10.1016/j.jhep.2010.09.002.
12. Mieli-Vergani G., Heller S., Jara P. et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009;49:158-164. doi: 10.1097/MPG.0b013e3181a1c265.
13. Gregorio G. V., Portmann B., Karani J., Harrison P., Donaldson P. T., Vergani D. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544-553. doi: 10.1053/jhep.2001.22131.
14. Beaune P., Dansette P. M., Mansuy D. et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A.1987;84:551-555. doi: 10.1073/pnas.84.2.551.
15. Bourdi M., Larrey D., Nataf J. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990;85:1967-1973. doi: 10.1172/JCI114660.
16. Muratori P., Granito A., Quarneti C. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol. 2009;50:1210-1218. doi: 10.1016/j.jhep.2009.01.020.
17. Zachou K., Gatselis N., Papadamou G., Rigopoulou E. I., Dalekos G. N. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011;55:636-646. doi: 10.1016/j.jhep.2010.12.032.
18. Obermayer-Straub P., Perheentupa J., Braun S. et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology. 2001;121:668-677. doi: 10.1053/gast.2001.27103.
Review
For citations:
Lebedeva T.N., Marchukova A.U., Bondar K.G. The debut of autoimmune hepatitis after a new coronavirus infection (COVID-19) in an 11-month-old child. Experimental and Clinical Gastroenterology. 2023;(8):191-196. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-216-8-191-196
Views:
1201
Email this article 